Table 1. summary of the rate of patients who received post-progression systemic treatments in clinical trials with EGFR-TKIs.

Study	EGFR-TKI	Post-progression treatment*, %
IPASS, Fukuoka et al., J Clin Oncol 2011	Gefitinib	76
NEJ002, Inoue et al., Ann Oncol 2013	Gefitinib	72
WJTOG 3405, Yoshioka et al., Ann Oncol 2019	Gefitinib	86
EURTAC, Rosell et al., Lancet Oncol 2012	Erlotinib	68
OPTIMAL, Zhou et al., Ann Oncol 2015	Erlotinib	63
LUX-LUNG 3, Yang et al., Lancet Oncol 2015	Afatinib	71
LUX-LUNG 6, Yang et al., Lancet Oncol 2015	Afatinib	57
LUX-LUNG 7, Paz-Ares et al., Ann Oncol 2017	Afatinib	73
	Gefitinib	77
FLAURA, Ramalingam et al., N Engl J Med 2020	Osimertinib	60
	Erlotinib/gefitinib	68

*, After discontinuation of study treatment, excludes patients remaining on assigned treatment at data cut-off, pre-progression treatment and death. EGFR-TKI, epidermal growth factor receptor-tyrosine kinase inhibitor.